Head-to-head comparison
| Property | Thymosin Alpha-1 | Thymalin |
|---|---|---|
| Category | Immune | Immune |
| Legal Status | Legal Compounding | Research Only |
| Primary Route | subcutaneous | intramuscular |
| Half-life | ~2 hours (plasma); peak serum levels at 1–2 hours post-injection | ~3-4 hours (estimated) |
| Mol. Weight | 3,108.28 Da | — |
| Side Effects | Injection site discomfort, Mild flu-like symptoms (transient), Fatigue | Injection site reactions, Mild allergic reactions (rare), Low-grade fever (immune activation) |
Key differences
- Molecular definition: Thymosin alpha-1 is a precisely characterized 28-amino-acid peptide with known sequence; thymalin is a dipeptide bioregulator (Glu-Trp) from Khavinson's peptide bioregulation research.
- Regulatory status: Thymosin alpha-1 is approved in over 30 countries (as Zadaxin) for hepatitis B and as an immune adjuvant; thymalin is approved in Russia as a bioregulator.
- Clinical evidence: Thymosin alpha-1 has extensive published clinical trials including in hepatitis B, hepatitis C, cancer immunotherapy, and immunodeficiency; thymalin's evidence is primarily from Russian research with limited Western peer review.
- Mechanism: Thymosin alpha-1 activates dendritic cells, enhances T-cell maturation, and modulates Th1/Th2 balance; thymalin's mechanism is described in terms of bioregulation theory — restoring optimal thymic function through gene expression modulation.
- Manufacturing: Thymosin alpha-1 is produced by chemical synthesis with precise purity standards; thymalin is a synthetic dipeptide.
- Molecular weight: Thymosin alpha-1 is approximately 3,108 Da; thymalin (Glu-Trp) is approximately 333 Da — an order of magnitude smaller.
- Research tradition: Thymosin alpha-1 was developed by Allan Goldstein at George Washington University; thymalin by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
The verdict
Thymosin alpha-1 is the more internationally validated option with regulatory approvals in over 30 countries and a robust body of Western clinical evidence. Thymalin is valued within the Russian bioregulation tradition and Khavinson's longevity research, but has limited independent Western validation. For evidence-based immune modulation, thymosin alpha-1 is the stronger choice. Thymalin is of interest within the bioregulator peptide framework, particularly for those already engaged with Khavinson's research program.
Frequently asked questions
Thymosin alpha-1 is not FDA-approved in the United States but is approved in over 30 other countries as Zadaxin for hepatitis B treatment and immune enhancement. It has been studied in FDA-registered clinical trials. Thymalin is approved in Russia as a bioregulator.
Both are thymus-derived immune modulators, and some Khavinson protocols include thymalin alongside other peptides. However, their overlapping immune targets suggest potential redundancy. No clinical studies have specifically evaluated this combination.
Thymosin alpha-1 has substantially more clinical evidence by international standards, with published trials in hepatitis, cancer immunotherapy, and immunodeficiency across multiple countries. Thymalin's evidence is primarily from Russian bioregulation research with limited Western peer-reviewed replication.
Bioregulation is a framework developed by Vladimir Khavinson proposing that short peptides (2-4 amino acids) can regulate gene expression in their tissue of origin. Thymalin is a thymic bioregulator peptide proposed to restore optimal thymic function. This framework is established in Russian medicine but has limited adoption in Western clinical practice.
Thymosin alpha-1 has stronger international clinical evidence for immune modulation, including in immunocompromised patients and as a cancer immunotherapy adjuvant. Thymalin is supported by Russian clinical research with positive outcomes reported. For evidence-based immune support with the broadest validation, thymosin alpha-1 is the stronger choice.